| Name |
Date |
Price (USD) |
Description |
|
Abbott Laboratories: PharmaVitae Profile |
19-Dec-07 |
5700 |
This analysis examines the historical and forecast performance for Abbott in
the ethical pharmaceutical sector. The profile encompasses global company strategy,
portfolio and pipeline analysis and assessment of financial performance, with
1-6 year sales forecasts for key drugs. An interactive forecasting and analysis
tool provides continually updated quantitative and qualitative information. |
|
Actelion: PharmaVitae Profile |
18-Oct-07 |
5700 |
This analysis examines the historical and forecast performance for Actelion in
the ethical pharmaceutical sector. The profile encompasses global company strategy,
portfolio and pipeline analysis and assessment of financial performance, with
1-6 year sales forecasts for key drugs. An interactive forecasting and analysis
tool provides continually updated quantitative and qualitative information |
|
Allergan Inc: PharmaVitae Profile |
12-Dec-07 |
5700 |
This analysis examines the historical and forecast performance for Allergan in
the ethical pharmaceutical sector. The profile encompasses global company strategy,
portfolio and pipeline analysis and assessment of financial performance, with
1-6 year sales forecasts for key drugs. An interactive forecasting and analysis
tool provides continually updated quantitative and qualitative information. |
|
Almirall: PharmaVitae Profile |
12-Apr-07 |
5700 |
This analysis examines the historical and forecast performance for Almirall in
the ethical pharmaceutical sector. The profile encompasses global company strategy,
portfolio and pipeline analysis and assessment of financial performance, with
1-6 year sales forecasts for key drugs. An interactive forecasting and analysis
tool provides continually updated quantitative and qualitative information. |
|
Amgen Inc: PharmaVitae Profile |
19-Dec-07 |
5700 |
This analysis examines the historical and forecast performance for Amgen in the
ethical pharmaceutical sector. The profile encompasses global company strategy,
portfolio and pipeline analysis and assessment of financial performance, with
1-6 year sales forecasts for key drugs. An interactive forecasting and analysis
tool provides continually updated quantitative and qualitative information. |
| Astellas Pharma Inc: PharmaVitae Profile |
19-Dec-07 |
5700 |
This analysis examines the historical and forecast performance for Astellas in
the ethical pharmaceutical sector. The profile encompasses global company strategy,
portfolio and pipeline analysis and assessment of financial performance, with
1-6 year sales forecasts for key drugs. An interactive forecasting and analysis
tool provides continually updated quantitative and qualitative information. |
|
AstraZeneca Plc (incl MedImmune Inc): PharmaVitae Profile |
19-Dec-07 |
5700 |
This analysis examines the historical and forecast performance for AstraZeneca
in the ethical pharmaceutical sector. The profile encompasses global company strategy,
portfolio and pipeline analysis and assessment of financial performance, with
1-6 year sales forecasts for key drugs. An interactive forecasting and analysis
tool provides continually updated quantitative and qualitative information. |
|
Barr: PharmaVitae Generics Profile |
03-Oct-07 |
3800 |
This analysis examines the historical and forecast performance for Barr in the
generic pharmaceutical sector. The profile encompasses global company strategy,
portfolio and pipeline analysis and assessment of financial performance. An interactive
data and analysis tool provides quantitative and qualitative information. |
|
Bayer Schering Pharma AG: PharmaVitae Profile |
12-Dec-07 |
5700 |
This analysis examines the historical and forecast performance for Bayer Schering
in the ethical pharma sector. The profile encompasses global company strategy,
portfolio and pipeline analysis and assessment of financial performance, with
1-6 year sales forecasts for key drugs. An interactive forecasting and analysis
tool provides continually updated quantitative and qualitative information. |
|
Biogen Idec Inc: PharmaVitae Profile |
19-Dec-07 |
5700 |
This analysis examines the historical and forecast performance for Biogen Idec
in the ethical pharmaceutical sector. The profile encompasses global company strategy,
portfolio and pipeline analysis and assessment of financial performance, with
1-6 year sales forecasts for key drugs. An interactive forecasting and analysis
tool provides continually updated quantitative and qualitative information. |
| Boehringer Ingelheim GmbH: PharmaVitae Profile |
25-Dec-07 |
5700 |
This analysis examines the historical and forecast performance for Boehringer
Ingelheim in the ethical pharma sector. The profile encompasses global company
strategy, portfolio and pipeline analysis and assessment of financial performance,
with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis
tool provides continually updated quantitative and qualitative information. |
|
Bracco: Company Profile |
26-Feb-07 |
2000 |
This Company Profile examines the performance of Bracco in the medical device
sector. The profile encompasses global company strategy and portfolio analysis,
and an assessment of financial performance. |
|
Bristol-Myers Squibb Co: PharmaVitae Profile |
19-Dec-07 |
5700 |
This analysis examines the historical and forecast performance for BMS in the
ethical pharmaceutical sector. The profile encompasses global company strategy,
portfolio and pipeline analysis and assessment of financial performance, with
1-6 year sales forecasts for key drugs. An interactive forecasting and analysis
tool provides continually updated quantitative and qualitative information. |
|
Bristol-Myers Squibb Co: PharmaVitae Profile |
30-Mar-07 |
5700 |
This analysis examines the historical and forecast performance for BMS in the
ethical pharmaceutical sector. The profile encompasses global company strategy,
portfolio and pipeline analysis and assessment of financial performance, with
1-6 year sales forecasts for key drugs. An interactive forecasting and analysis
tool provides continually updated quantitative and qualitative information. |
|
Cardinal Health: Company Profile |
26-Feb-07 |
2000 |
This Company Profile examines the performance of Cardinal Health in the medical
device sector. The profile encompasses global company strategy and portfolio analysis,
and an assessment of financial performance. |
|
Cephalon Inc: PharmaVitae Profile |
19-Dec-07 |
5700 |
This analysis examines the historical and forecast performance for Cephalon in
the ethical pharmaceutical sector. The profile encompasses global company strategy,
portfolio and pipeline analysis and assessment of financial performance, with
1-6 year sales forecasts for key drugs. An interactive forecasting and analysis
tool provides continually updated quantitative and qualitative information. |
|
Chugai: PharmaVitae Profile |
18-Oct-07 |
5700 |
This analysis examines the historical and forecast performance for Chugai in
the ethical pharmaceutical sector. The profile encompasses global company strategy,
portfolio and pipeline analysis and assessment of financial performance, with
1-6 year sales forecasts for key drugs. An interactive forecasting and analysis
tool provides continually updated quantitative and qualitative information. |
|
Daiichi Sankyo Co Ltd: PharmaVitae Profile |
19-Dec-07 |
5700 |
This analysis examines the historical and forecast performance for Daiichi Sankyo
in the ethical pharma sector. The profile encompasses global company strategy,
portfolio and pipeline analysis and assessment of financial performance, with
1-6 year sales forecasts for key drugs. An interactive forecasting and analysis
tool provides continually updated quantitative and qualitative information. |
|
Dainippon Sumitomo Pharma Co Ltd: PharmaVitae Profile
|
19-Dec-07
|
5700 |
This analysis examines the historical and forecast performance for Dainippon
Sumitomo in the ethical pharma sector. The profile encompasses global company
strategy, portfolio and pipeline analysis and assessment of financial performance,
with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis
tool provides continually updated quantitative and qualitative information. |
|
Eisai Co Ltd: PharmaVitae Profile |
19-Dec-07 |
5700 |
This analysis examines the historical and forecast performance for Eisai in the
ethical pharmaceutical sector. The profile encompasses global company strategy,
portfolio and pipeline analysis and assessment of financial performance, with
1-6 year sales forecasts for key drugs. An interactive forecasting and analysis
tool provides continually updated quantitative and qualitative information. |
|
Eli Lilly & Co: PharmaVitae Profile |
19-Dec-07 |
5700 |
This analysis examines the historical and forecast performance for Eli Lilly
in the ethical pharmaceutical sector. The profile encompasses global company strategy,
portfolio and pipeline analysis and assessment of financial performance, with
1-6 year sales forecasts for key drugs. An interactive forecasting and analysis
tool provides continually updated quantitative and qualitative information. |
|
Forest Laboratories Inc: PharmaVitae Profile |
19-Dec-07 |
5700 |
This analysis examines the historical and forecast performance for Forest in
the ethical pharmaceutical sector. The profile encompasses global company strategy,
portfolio and pipeline analysis and assessment of financial performance, with
1-6 year sales forecasts for key drugs. An interactive forecasting and analysis
tool provides continually updated quantitative and qualitative information. |
|
Genzyme Corporation: PharmaVitae Profile |
12-Dec-07 |
5700 |
This analysis examines the historical and forecast performance for Genzyme in
the ethical pharmaceutical sector. The profile encompasses global company strategy,
portfolio and pipeline analysis and assessment of financial performance, with
1-6 year sales forecasts for key drugs. An interactive forecasting and analysis
tool provides continually updated quantitative and qualitative information. |
|
Gilead: PharmaVitae Profile |
18-Jan-07 |
5700 |
This analysis examines the historical and forecast performance for Gilead in
the ethical pharmaceutical sector. The profile encompasses global company strategy,
portfolio and pipeline analysis and assessment of financial performance, with
1-6 year sales forecasts for key drugs. An interactive forecasting and analysis
tool provides continually updated quantitative and qualitative information. |
|
Gilead Sciences Inc: PharmaVitae Profile |
19-Dec-07 |
5700 |
This analysis examines the historical and forecast performance for Gilead in
the ethical pharmaceutical sector. The profile encompasses global company strategy,
portfolio and pipeline analysis and assessment of financial performance, with
1-6 year sales forecasts for key drugs. An interactive forecasting and analysis
tool provides continually updated quantitative and qualitative information. |
|
Genentech: PharmaVitae Profile |
18-Oct-07 |
5700 |
This analysis examines the historical and forecast performance for Genentech
in the ethical pharmaceutical sector. The profile encompasses global company strategy,
portfolio and pipeline analysis and assessment of financial performance, with
1-6 year sales forecasts for key drugs. An interactive forecasting and analysis
tool provides continually updated quantitative and qualitative information. |
|
GlaxoSmithKline Plc: PharmaVitae Profile |
14-Nov-07 |
5700 |
This analysis examines the historical and forecast performance for GSK in the
ethical pharmaceutical sector. The profile encompasses global company strategy,
portfolio and pipeline analysis and assessment of financial performance, with
1-6 year sales forecasts for key drugs. An interactive forecasting and analysis
tool provides continually updated quantitative and qualitative information. |
|
Guerbet: Company Profile |
26-Feb-07 |
2000 |
This Company Profile examines the performance of Guerbet in the medical device
sector. The profile encompasses global company strategy and portfolio analysis,
and an assessment of financial performance. |
|
H Lundbeck AS: PharmaVitae Profile |
19-Dec-07 |
5700 |
This analysis examines the historical and forecast performance for Lundbeck in
the ethical pharmaceutical sector. The profile encompasses global company strategy,
portfolio and pipeline analysis and assessment of financial performance, with
1-6 year sales forecasts for key drugs. An interactive forecasting and analysis
tool provides continually updated quantitative and qualitative information. |
|
Ipsen: PharmaVitae Profile |
21-Mar-07 |
5700 |
This analysis examines the historical and forecast performance for Ipsen in the
ethical pharmaceutical sector. The profile encompasses global company strategy,
portfolio and pipeline analysis and assessment of financial performance, with
1-6 year sales forecasts for key drugs. An interactive forecasting and analysis
tool provides continually updated quantitative and qualitative information. |
|
Johnson & Johnson: PharmaVitae Profile |
19-Dec-07 |
5700 |
This analysis examines the historical and forecast performance for J&J in
the ethical pharmaceutical sector. The profile encompasses global company strategy,
portfolio and pipeline analysis and assessment of financial performance, with
1-6 year sales forecasts for key drugs. An interactive forecasting and analysis
tool provides continually updated quantitative and qualitative information. |
|
King Pharmaceuticals: PharmaVitae Profile |
13-Nov-07 |
5700 |
This analysis examines the historical and forecast performance for King in the
ethical pharmaceutical sector. The profile encompasses global company strategy,
portfolio and pipeline analysis and assessment of financial performance, with
1-6 year sales forecasts for key drugs. An interactive forecasting and analysis
tool provides continually updated quantitative and qualitative information. |
|
Les Laboratoire Servier: PharmaVitae Profile
|
25-Dec-07 |
5700 |
This analysis examines the historical and forecast performance for Servier in
the ethical pharmaceutical sector. The profile encompasses global company strategy,
portfolio and pipeline analysis and assessment of financial performance, with
1-6 year sales forecasts for key drugs. An interactive forecasting and analysis
tool provides continually updated quantitative and qualitative information. |
|
MedImmune Inc: PharmaVitae Profile |
14-Nov-07 |
5700 |
This analysis examines the historical and forecast performance for MedImmune
in the ethical pharmaceutical sector. The profile encompasses global company strategy,
portfolio and pipeline analysis and assessment of financial performance, with
1-6 year sales forecasts for key drugs. An interactive forecasting and analysis
tool provides continually updated quantitative and qualitative information. |
|
Menarini: PharmaVitae Profile |
22-Mar-07 |
5700 |
This analysis examines the historical and forecast performance for Menarini in
the ethical pharmaceutical sector. The profile encompasses global company strategy,
portfolio and pipeline analysis and assessment of financial performance, with
1-6 year sales forecasts for key drugs. An interactive forecasting and analysis
tool provides continually updated quantitative and qualitative information. |
|
Menarini: PharmaVitae Profile |
19-Dec-07 |
5700 |
This analysis examines the historical and forecast performance for Menarini in
the ethical pharmaceutical sector. The profile encompasses global company strategy,
portfolio and pipeline analysis and assessment of financial performance, with
1-6 year sales forecasts for key drugs. An interactive forecasting and analysis
tool provides continually updated quantitative and qualitative information. |
|
Merck & Co Inc: PharmaVitae Profile |
19-Dec-07 |
5700 |
This analysis examines the historical and forecast performance for Merck &
Co. in the ethical pharmaceutical sector. The profile encompasses global company
strategy, portfolio and pipeline analysis and assessment of financial performance,
with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis
tool provides continually updated quantitative and qualitative information. |
|
Merck Serono SA: PharmaVitae Profile |
19-Dec-07 |
5700 |
This analysis examines the historical and forecast performance for Merck-Serono
in the ethical pharmaceutical sector. The profile encompasses global company strategy,
portfolio and pipeline analysis and assessment of financial performance, with
1-6 year sales forecasts for key drugs. An interactive forecasting and analysis
tool provides continually updated quantitative and qualitative information. |
|
Millenium: PharmaVitae Profile |
26-Feb-07 |
5700 |
This analysis examines the historical and forecast performance for Millennium
in the ethical pharmaceutical sector. The profile encompasses global company strategy,
portfolio and pipeline analysis and assessment of financial performance, with
1-6 year sales forecasts for key drugs. An interactive forecasting and analysis
tool provides continually updated quantitative and qualitative information. |
|
Mitsubishi Tanabe Pharma Corporation: PharmaVitae Profile |
19-Dec-07 |
5700 |
This analysis examines the historical and forecast performance for Mitsubishi
Tanabe in the ethical pharma sector. The profile encompasses global company strategy,
portfolio and pipeline analysis and assessment of financial performance, with
1-6 year sales forecasts for key drugs. An interactive forecasting and analysis
tool provides continually updated quantitative and qualitative information |
|
Mylan: PharmaVitae Generics Profile |
14-Nov-07
|
5700 |
This analysis examines the historical and forecast performance for Mylan in the
generic pharmaceutical sector. The profile encompasses global company strategy,
portfolio and pipeline analysis and assessment of financial performance, with
1-6 year sales forecasts for key branded drugs. An interactive data and analysis
tool provides quantitative and qualitative information. |
|
Novartis AG: PharmaVitae Profile |
13-Nov-07 |
5700 |
This analysis examines the historical and forecast performance for Novartis in
the ethical pharmaceutical sector. The profile encompasses global company strategy,
portfolio and pipeline analysis and assessment of financial performance, with
1-6 year sales forecasts for key drugs. An interactive forecasting and analysis
tool provides continually updated quantitative and qualitative information. |
|
Novo Nordisk A/S: PharmaVitae Profile |
31-Oct-07 |
5700 |
This analysis examines the historical and forecast performance for Novo Nordisk
in the ethical pharmaceutical sector. The profile encompasses global company strategy,
portfolio and pipeline analysis and assessment of financial performance, with
1-6 year sales forecasts for key drugs. An interactive forecasting and analysis
tool provides continually updated quantitative and qualitative information. |
| Nycomed AS (incl Altana Pharma AG): PharmaVitae Profile |
12-Dec-07 |
5700 |
This analysis examines the historical and forecast performance for Nycomed in
the ethical pharmaceutical sector. The profile encompasses global company strategy,
portfolio and pipeline analysis and assessment of financial performance, with
1-6 year sales forecasts for key drugs. An interactive forecasting and analysis
tool provides continually updated quantitative and qualitative information. |
|
Organon: PharmaVitae Profile |
31-Oct-07 |
5700 |
This analysis examines the historical and forecast performance for Organon in
the ethical pharmaceutical sector. The profile encompasses global company strategy,
portfolio and pipeline analysis and assessment of financial performance, with
1-6 year sales forecasts for key drugs. An interactive forecasting and analysis
tool provides continually updated quantitative and qualitative information. |
|
Pfizer Inc: PharmaVitae Profile |
19-Dec-07 |
5700 |
This analysis examines the historical and forecast performance for Pfizer in
the ethical pharmaceutical sector. The profile encompasses global company strategy,
portfolio and pipeline analysis and assessment of financial performance, with
1-6 year sales forecasts for key drugs. An interactive forecasting and analysis
tool provides continually updated quantitative and qualitative information. |
|
Philips Medical Systems: Company Profile |
26-Feb-07 |
2000 |
This Company Profile examines the performance of Philips Medical Systems in the
medical device sector. The profile encompasses global company strategy and portfolio
analysis, and an assessment of financial performance. |
|
Roche: PharmaVitae Profile |
18-Oct-07 |
5700 |
This analysis examines the historical and forecast performance for Roche in the
ethical pharmaceutical sector. The profile encompasses global company strategy,
portfolio and pipeline analysis and assessment of financial performance, with
1-6 year sales forecasts for key drugs. An interactive forecasting and analysis
tool provides continually updated quantitative and qualitative information. |
|
Sandoz: PharmaVitae Generics Profile |
03-Oct-07 |
3800 |
This analysis examines the historical and forecast performance for Sandoz in
the generic pharmaceutical sector. The profile encompasses global company strategy,
generic and biosimilar portfolio and pipeline analysis and assessment of financial
performance. An interactive data and analysis tool provides quantitative and qualitative
information. |
|
Sanofi-Aventis: PharmaVitae Profile |
19-Dec-07 |
5700 |
This analysis examines the historical and forecast performance for Sanofi-Aventis
in the ethical pharma sector. The profile encompasses global company strategy,
portfolio and pipeline analysis and assessment of financial performance, with
1-6 year sales forecasts for key drugs. An interactive forecasting and analysis
tool provides continually updated quantitative and qualitative information. |
|
Schering-Plough Corporation: PharmaVitae Profile |
14-Nov-07 |
5700 |
This analysis examines the historical and forecast performance for Schering-Plough
in the ethical pharmaceutical sector. It encompasses global company strategy,
portfolio and pipeline analysis and assessment of financial performance, with
1-6 year sales forecasts for key drugs. An interactive forecasting and analysis
tool provides continually updated quantitative and qualitative information. |
| Sepracor Inc: PharmaVitae Profile |
25-Dec-07 |
5700 |
This analysis examines the historical and forecast performance for Sepracor in
the ethical pharmaceutical sector. The profile encompasses global company strategy,
portfolio and pipeline analysis and assessment of financial performance, with
1-6 year sales forecasts for key drugs. An interactive forecasting and analysis
tool provides continually updated quantitative and qualitative information. |
|
Servier: PharmaVitae Profile |
26-Feb-07 |
5700 |
This analysis examines the historical and forecast performance for Servier in
the ethical pharmaceutical sector. The profile encompasses global company strategy,
portfolio and pipeline analysis and assessment of financial performance, with
1-6 year sales forecasts for key drugs. An interactive forecasting and analysis
tool provides continually updated quantitative and qualitative information. |
|
Shionogi & Co Ltd: PharmaVitae Profile |
19-Dec-07 |
5700 |
This analysis examines the historical and forecast performance for Shionogi in
the ethical pharmaceutical sector. The profile encompasses global company strategy,
portfolio and pipeline analysis and assessment of financial performance, with
1-6 year sales forecasts for key drugs. An interactive forecasting and analysis
tool provides continually updated quantitative and qualitative information. |
|
Shire Plc: PharmaVitae Profile |
19-Dec-07 |
5700 |
This analysis examines the historical and forecast performance for Shire in the
ethical pharmaceutical sector. The profile encompasses global company strategy,
portfolio and pipeline analysis and assessment of financial performance, with
1-6 year sales forecasts for key drugs. An interactive forecasting and analysis
tool provides continually updated quantitative and qualitative information |
|
Solvay SA: PharmaVitae Profile |
21-Mar-07 |
5700 |
This analysis examines the historical and forecast performance for Solvay in
the ethical pharmaceutical sector. The profile encompasses global company strategy,
portfolio and pipeline analysis and assessment of financial performance, with
1-6 year sales forecasts for key drugs. An interactive forecasting and analysis
tool provides continually updated quantitative and qualitative information. |
|
Solvay SA: PharmaVitae Profile |
25-Dec-07 |
5700 |
This analysis examines the historical and forecast performance for Solvayin the
ethical pharmaceutical sector. The profile encompasses global company strategy,
portfolio and pipeline analysis and assessment of financial performance, with
1-6 year sales forecasts for key drugs. An interactive forecasting and analysis
tool provides continually updated quantitative and qualitative information. |
|
Takeda Pharmaceutical Co Ltd: PharmaVitae Profile |
19-Dec-07 |
5700 |
This analysis examines the historical and forecast performance for Takeda in
the ethical pharmaceutical sector. The profile encompasses global company strategy,
portfolio and pipeline analysis and assessment of financial performance, with
1-6 year sales forecasts for key drugs. An interactive forecasting and analysis
tool provides continually updated quantitative and qualitative information. |
|
Teva: PharmaVitae Generics Profile |
31-Jul-07 |
3800 |
This analysis examines the historical and forecast performance for Teva in the
generic pharmaceutical sector. The profile encompasses global company strategy,
portfolio and pipeline analysis and assessment of financial performance, with
1-6 year sales forecasts for key branded drugs. An interactive data and analysis
tool provides additional quantitative and qualitative information. |
|
Toshiba: Company Profile |
26-Feb-07 |
2000 |
This Company Profile examines the performance of Toshiba in the medical device
sector. The profile encompasses global company strategy and portfolio analysis,
and an assessment of financial performance. |
|
UCB SA: PharmaVitae Profile |
14-Nov-07 |
5700 |
This analysis examines the historical and forecast performance for UCB in the
ethical pharmaceutical sector. The profile encompasses global company strategy,
portfolio and pipeline analysis and assessment of financial performance, with
1-6 year sales forecasts for key drugs. An interactive forecasting and analysis
tool provides continually updated quantitative and qualitative information. |
|
Watson: PharmaVitae Generics Profile |
14-Sep-07 |
3800 |
This analysis examines the historical and forecast performance for Watson in
the generic pharmaceutical sector. The profile encompasses global company strategy,
portfolio and pipeline analysis and assessment of financial performance, with
1-6 year sales forecasts for key branded drugs. An interactive data and analysis
tool provides quantitative and qualitative information. |
|
Wyeth: PharmaVitae Profile |
19-Dec-07 |
5700 |
This analysis examines the historical and forecast performance for Wyeth in the
ethical pharmaceutical sector. The profile encompasses global company strategy,
portfolio and pipeline analysis and assessment of financial performance, with
1-6 year sales forecasts for key drugs. An interactive forecasting and analysis
tool provides continually updated quantitative and qualitative information. |
